Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01149499 · ClinicalTrials.gov registry record · Phase 1

Valacyclovir 1000 mg Tablet Under Fasting Conditions

A Phase 1 study of Healthy, sponsored by Teva Pharmaceuticals U.

Completed
Registry status
Phase 1
Development phase
60
Enrollment target
1
Study location

NCT01149499: Completed Phase 1 study of Healthy, sponsored by Teva Pharmaceuticals U.

NCT01149499 is a Phase 1 study of Healthy that has completed, run by Teva Pharmaceuticals U. The registered enrollment target is 60 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01149499, a Phase 1 study of Healthy, has completed, sponsored by Teva Pharmaceuticals U.

COMPLETED
Registry status
Phase 1
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to compare the rate and extent of absorption of valacyclovir 1000 mg tablet (test) versus Valtrex (reference), administered as 1 x 1000 mg tablet under fasting conditions.

Primary Outcome

Bioequivalence based on Cmax

Conditions Studied

Interventions

  • DRUG Valacyclovir

Study Locations (1)

Minnesota

  • PRACS Institute, Ltd. - East Grand Forks

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2005-01
Est. Completion 2005-01
Phase Phase 1
Teva Pharmaceuticals U

19 total trials

What the finished NCT01149499 record still lists

NCT01149499 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Valacyclovir is the first listed.

NCT01149499 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT01149499 about?

NCT01149499 is a clinical study titled "Valacyclovir 1000 mg Tablet Under Fasting Conditions". The objective of this study is to compare the rate and extent of absorption of valacyclovir 1000 mg tablet (test) versus Valtrex (reference), administered as 1 x 1000 mg tablet under fasting conditions.

What is the current status of trial NCT01149499?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2005-01. Estimated completion is 2005-01.

What conditions does trial NCT01149499 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01149499?

The interventions under investigation include: Valacyclovir (DRUG).

Who is sponsoring clinical trial NCT01149499?

This trial is sponsored by Teva Pharmaceuticals U, which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01149499 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01149499's enrollment target sits among peer trials

60 369th of 1090 higher than 689 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01149499, the US trial registry maintained by the National Library of Medicine. NCT01149499 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.